Statin use and outcomes of oncological treatment for castration-resistant prostate cancer
Abstract To compare the effect of statin use in relation to castration-resistant prostate cancer (CRPC) treatment, we assessed the risk of ADT-treated PCa-patients to initiate CRPC treatment by statin use and the outcomes of CRPC treatment by statin use. Our study cohort consisted of 1169 men who pa...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-11-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-45958-8 |
| _version_ | 1797636864250740736 |
|---|---|
| author | A. I. Peltomaa K. Talala K. Taari T. L. J. Tammela A. Auvinen T. J. Murtola |
| author_facet | A. I. Peltomaa K. Talala K. Taari T. L. J. Tammela A. Auvinen T. J. Murtola |
| author_sort | A. I. Peltomaa |
| collection | DOAJ |
| description | Abstract To compare the effect of statin use in relation to castration-resistant prostate cancer (CRPC) treatment, we assessed the risk of ADT-treated PCa-patients to initiate CRPC treatment by statin use and the outcomes of CRPC treatment by statin use. Our study cohort consisted of 1169 men who participated in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) and initiated androgen deprivation therapy (ADT) during the follow-up (1996–2017). Statin use was associated with slightly decreased risk of initiating CRPC treatment (HR 0.68; 95% CI 0.47–0.97) with a 5.7 years’ median follow-up until CRPC for non-users and 7.5 years for statin users. The risk of discontinuation of first or second line CRPC treatment due to inefficacy was not modified by statin use and the results remained similar in subgroup analysis assessing separately patients treated with taxans or androgen receptor signaling inhibitors. We observed an inverse association between statin use and the risk of initiation of the CRPC treatment. No beneficial risk modification by statin use during CRPC treatment was observed. These results suggest that statins might be beneficial during hormone-sensitive phase but not in the later phases of prostate cancer treatment. |
| first_indexed | 2024-03-11T12:41:23Z |
| format | Article |
| id | doaj.art-1366b304409d469482ca76bea1f8b26a |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-11T12:41:23Z |
| publishDate | 2023-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-1366b304409d469482ca76bea1f8b26a2023-11-05T12:17:36ZengNature PortfolioScientific Reports2045-23222023-11-011311910.1038/s41598-023-45958-8Statin use and outcomes of oncological treatment for castration-resistant prostate cancerA. I. Peltomaa0K. Talala1K. Taari2T. L. J. Tammela3A. Auvinen4T. J. Murtola5Faculty of Medicine and Health Technology, Tampere University and Tampere University HospitalFinnish Cancer RegistryDepartment of Urology, University of Helsinki and Helsinki University HospitalFaculty of Medicine and Health Technology, Tampere University and Tampere University HospitalFaculty of Social Sciences, Tampere UniversityFaculty of Medicine and Health Technology, Tampere University and Tampere University HospitalAbstract To compare the effect of statin use in relation to castration-resistant prostate cancer (CRPC) treatment, we assessed the risk of ADT-treated PCa-patients to initiate CRPC treatment by statin use and the outcomes of CRPC treatment by statin use. Our study cohort consisted of 1169 men who participated in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) and initiated androgen deprivation therapy (ADT) during the follow-up (1996–2017). Statin use was associated with slightly decreased risk of initiating CRPC treatment (HR 0.68; 95% CI 0.47–0.97) with a 5.7 years’ median follow-up until CRPC for non-users and 7.5 years for statin users. The risk of discontinuation of first or second line CRPC treatment due to inefficacy was not modified by statin use and the results remained similar in subgroup analysis assessing separately patients treated with taxans or androgen receptor signaling inhibitors. We observed an inverse association between statin use and the risk of initiation of the CRPC treatment. No beneficial risk modification by statin use during CRPC treatment was observed. These results suggest that statins might be beneficial during hormone-sensitive phase but not in the later phases of prostate cancer treatment.https://doi.org/10.1038/s41598-023-45958-8 |
| spellingShingle | A. I. Peltomaa K. Talala K. Taari T. L. J. Tammela A. Auvinen T. J. Murtola Statin use and outcomes of oncological treatment for castration-resistant prostate cancer Scientific Reports |
| title | Statin use and outcomes of oncological treatment for castration-resistant prostate cancer |
| title_full | Statin use and outcomes of oncological treatment for castration-resistant prostate cancer |
| title_fullStr | Statin use and outcomes of oncological treatment for castration-resistant prostate cancer |
| title_full_unstemmed | Statin use and outcomes of oncological treatment for castration-resistant prostate cancer |
| title_short | Statin use and outcomes of oncological treatment for castration-resistant prostate cancer |
| title_sort | statin use and outcomes of oncological treatment for castration resistant prostate cancer |
| url | https://doi.org/10.1038/s41598-023-45958-8 |
| work_keys_str_mv | AT aipeltomaa statinuseandoutcomesofoncologicaltreatmentforcastrationresistantprostatecancer AT ktalala statinuseandoutcomesofoncologicaltreatmentforcastrationresistantprostatecancer AT ktaari statinuseandoutcomesofoncologicaltreatmentforcastrationresistantprostatecancer AT tljtammela statinuseandoutcomesofoncologicaltreatmentforcastrationresistantprostatecancer AT aauvinen statinuseandoutcomesofoncologicaltreatmentforcastrationresistantprostatecancer AT tjmurtola statinuseandoutcomesofoncologicaltreatmentforcastrationresistantprostatecancer |